sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 137 NHL


News
1. Overview
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


HO137 news

07Jun2017: The trial will continue with Rixathon (rituximab biosimilar from Sandoz) instead of obinutuzumab. The new protocol is in development and participating sites are informed by email. 

 

31Aug2016: Trial has been set on hold. Reason for this is that the GOYA study (obinutuzumab treatment for DLBCL) didn't reach its primary endpoint. Currently there are discussions with Roche about the continuation of the HO137. As soon as there is more information, participating sites will be informed.


1. Overview



Status

planned


Type of study

Prospective randomized Phase II study


Echelon level

Level D


Type of monitoring for this study

Site evaluation visits


Target number of patients

170


2. Patient eligibility criteria



3. Registration (& randomization) of patients



4. Participating parties



5. Participating sites



6. Instruction videos



7. Download documentation / forms




return to top